FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 03/2024 published - FCF Fox Corporate Finance GmbH

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 03/2024”.

The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.

As of the end of March 2024 we identified the following current VC trends in the United States:

• Total Healthcare & Life Sciences funding reached EUR 8,217m
• Biotech received 61% of the total investment volume (EUR 5,037m) with oncology being the leading indication (31%)
• In March Mirador Therapeutics secures the highest transaction volume with EUR 368m, followed by Alumis with EUR 240m and Avenzo with EUR 205m
• Premji Invest (United States) is the most active investor (by deal volume), followed by RA Capital Management (United States) and Novo Holdings (Denmark)

To access the full report, please click here.